



## Correction to: Improvement in Cognitive Function as Measured by NeuroTrax in Patients with Relapsing Multiple Sclerosis Treated with Natalizumab: A 2-Year Retrospective Analysis

Mark Gudesblatt<sup>1</sup> · Karl Wissemann<sup>1</sup> · Myassar Zarif<sup>1</sup> · Barbara Bumstead<sup>1</sup> · Lori Fafard<sup>1</sup> · Jeffrey Wilken<sup>2</sup> · Karen Blitz<sup>1</sup> · Marijean Buhse<sup>1</sup> · Sourav Santra<sup>3</sup> · Christophe Hotermans<sup>3</sup> · Lily Lee<sup>3</sup> 

Published online: 22 September 2018  
© Springer Nature Switzerland AG 2018

**Correction to: CNS Drugs**  
<https://doi.org/10.1007/s40263-018-0553-1>

An Online First version of this article was made available online at <http://link.springer.com/journal/40263/onlineFirst/page/1> on 24 August 2018. An error was subsequently identified in the article, and the following correction should be noted:

Author listing: The name of the second author, which previously read:

‘Karl Wisseman’

Should read:

‘Karl Wissemann’.

The original article has been corrected.

---

The original article can be found online at <https://doi.org/10.1007/s40263-018-0553-1>.

---

✉ Lily Lee  
lily.lee@biogen.com

<sup>1</sup> South Shore Neurologic Associates, Patchogue, NY, USA

<sup>2</sup> Washington Neuropsychology Research Group LLC, Fairfax, VA, USA

<sup>3</sup> Biogen, 225 Binney Street, Cambridge, MA 02142, USA